Skip to main content
Premium Trial:

Request an Annual Quote

Mark Tepper


Microfluidics startup Arradial of Bedford, Mass., has appointed Mark Tepper as president and CEO, and John Havens as senior vice president of technology. Tepper comes to Arradial after serving as vice president of research and operations at the Serono Pharmaceutical Research Institute, where he was a member of the senior research management team and headed the company’s lead discovery efforts. Prior to holding this position, Tepper served in leadership positions at the Bristol-Myers Squibb Pharmaceutical Research Institute and the University of Massachusetts Medical School. Tepper holds a PhD in biochemistry and biophysics from Columbia University.

Havens comes to Arradial from Nanogen, where he served as senior director of chemistry and high-throughput screening, and developed SNP genotyping and SNP discovery efforts. He has two patents issued for Nanogen in the SNP platform area. He also supervised biomolecular attachment chemistry development on the company’s NanoChip platform, and led development of electronic kinase HTS assays and substrate-identification technologies. Havens is moving to Arradial, he said, because he specializes in startup companies.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.